Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in resectable MSI-H/dMMR colon cancer
NCT06686576Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Dec 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in colon cancer, sponsored by Qilu Pharmaceutical. Started Dec 2024; status: recruiting.
02
Drugs
QL1706
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06686576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686576.